GlassScriptPhysician profile
Jorge L Perez
NPI 1770520074
$17,206.18
in general payments reported to CMS, 2019-2025
30 companies · $7,395 in 2025
The $7,395 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,406 · 2020: $964 · 2021: $1,729 · 2022: $1,464 · 2023: $1,332 · 2024: $916 · 2025: $7,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,500 · Food and Beverage: $2,907 · Travel and Lodging: $1,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,500.00 |
| Food and Beverage | $2,907.30 |
| Travel and Lodging | $1,235.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,816.00 | 2022-2025 | |
| Novo Nordisk INC | $1,885.48 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $1,800.24 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $916.31 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $898.98 | 2021-2024 | |
| Amarin Pharma, INC. | $891.88 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $886.81 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $447.86 | 2019-2024 | |
| Abbvie INC. | $398.76 | 2021-2025 | |
| Pfizer INC. | $369.25 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $346.17 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $240.79 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $228.26 | 2019-2024 | Xarelto |
| Nestle Healthcare Nutrition INC. | $162.77 | 2021-2023 | |
| Astellas Pharma US INC | $118.37 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $114.28 | 2023 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $111.98 | 2021-2025 | Livalo, Seglentis, Zoryve |
| Biotissue Holdings INC. | $101.19 | 2022 | |
| Glaxosmithkline, LLC. | $91.43 | 2023 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $88.23 | 2019-2020 | |
| Amgen INC. | $54.97 | 2024-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $49.80 | 2019-2020 | |
| Abbott Laboratories | $43.52 | 2022-2023 | Freestyle Libre 2 |
| Eisai INC. | $27.05 | 2025 | |
| Exact Sciences Corporation | $24.71 | 2023 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $23.42 | 2025 | Zenpep |
| Boston Scientific Corporation | $20.30 | 2022 | |
| Merck Sharp & Dohme LLC | $18.06 | 2019 | |
| Gilead Sciences, INC. | $14.71 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.